Abstract:INTRODUCTION:With the ongoing COVID-19 pandemic, a number of rare complications have been reported.We present a case of a rare neurological complication in a patient with a newly diagnosed COVID-19 infection.CASE PRESENTATION: A 64-year-old man with recently treated intraabdominal infection (antibiotics and drainage) presented to the Emergency Department (ED) with a 3-day history of fevers, intermittent right-sided flank pain, and urinary symptoms.He was found to have a complicated urinary tract infection (UTI) due to Klebsiella pneumoniae.He was started on intravenous antibiotics.He was tested positive for the SARS-CoV2 virus.On day 5, he developed progressive hypoxemia with bilateral infiltrates on the chest x-ray.Remdesivir and dexamethasone were initiated.Despite that, the patient developed further progression of respiratory failure requiring intubation.He then failed extubation.On exam, the patient was noted to have profound bilateral lower extremity weakness (motor strength: upper extremities -4/5 bilaterally; lower extremities -2/5), absent deep tendon reflexes.Magnetic resonance imaging (MRI) of the brain and spine did not show any abnormal lesions.Lumbar puncture showed an elevated protein (147 (15-40 mg/dL)) with absent cells in the cerebrospinal fluid (CSF) (albuminocytologic dissociation).He was diagnosed with Guillain-Barré syndrome (GBS).Therapeutic plasma exchange (TPE) was initiated (IVIG was not recommended given the potential risk of hypercoagulability).The patient completed 5 days of TPE.The patient noted some improvement in the strength of upper extremities.Unfortunately, the patient later developed a multiorgan failure with recurrent aspiration events and renal failure.The patient and his family decided to proceed with hospice. DISCUSSION: GBS is a heterogenous acute immune-mediated polyneuropathy commonly triggered by various viral infections.There have been several reports of SARS-CoV-2 infection triggering both primary and recurrent GBS.It is thought to be induced by the cross-reactivity of viral antigens with myelin.The diagnosis of GBS should be suspected in patients with progressive symmetric muscle weakness and absent deep tendon reflexes.Electrodiagnostic (not done in our patient) and CSF studies are usually done to confirm the diagnosis.Albuminocytologic dissociation (elevated protein with normal WBC count in the CSF) can be detected in most patients, especially if CSF is obtained after 7 days since the onset of symptoms.Supportive treatment with close monitoring of respiratory function is extremely important in affected patients.Disease-modifying therapies include the use of IVIG or TPE.CONCLUSIONS: With the myriad of publications related to SARS-CoV-2 infection, we continue to learn more about the culprit virus.We believe that healthcare workers should be aware of autoimmune complications of COVID-19 infection given the ongoing pandemic.

Bioinformatic analyses hinted at augmented T helper 17 cell differentiation and cytokine response as the central mechanism of COVID‐19–associated Guillain‐Barré syndrome

Biological analysis of the potential pathogenic mechanisms of Infectious COVID-19 and Guillain-Barré syndrome

Guillain-Barré syndrome in southern China: retrospective analysis of hospitalised patients from 14 provinces in the area south of the Huaihe River.

Guillain Barre syndrome associated with COVID-19 infection: A case report

Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases

Prevalence, clinical characteristics and outcomes of Guillain−Barré syndrome spectrum associated with COVID‐19: A systematic review and meta‐analysis

COVID‐19‐associated Guillain‐Barre syndrome: Postinfectious alone or neuroinvasive too?

Guillain-Barré syndrome: immunopathogenesis and therapeutic targets

Guillain–Barre syndrome and link with COVID-19 infection and vaccination: a review of literature

Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review

Causal relationship between immune cells and Guillain-Barré syndrome: a Mendelian randomization study

Association of Guillain–Barré syndrome following COVID-19 vaccination

A Case of Guillain-Barré Syndrome Associated With COVID-19

COVID-19 AND NEUROLOGICAL AUTOIMMUNITY: A CASE OF SARS-COV-2-INDUCED GUILLAIN-BARRÉ SYNDROME

Guillain-Barre syndrome in 220 patients with COVID-19

SARS-CoV-2-associated Guillain-Barré syndrome in four patients: what do we know about pathophysiology?

COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain–Barré syndrome

Integrating single-cell sequencing data with GWAS summary statistics reveals CD16+monocytes and memory CD8+T cells involved in severe COVID-19

Covid-19 associated Guillain-Barré syndrome: A series of a relatively uncommon neurological complication

Causal effects of systemic inflammatory proteins on Guillain-Barre Syndrome: insights from genome-wide Mendelian randomization, single-cell RNA sequencing analysis, and network pharmacology

Relation between Guillain-Barré syndrome and Covid-19: Case-Series